May 9, 2012
Mitsubishi Tanabe Pharma Corporation (MTPC) announced on May 8 that the condition of approval for psoriasis of the anti-human TNFα monochlonal antibody Remicade for IV Infusion 100 (infliximab) has been lifted. In 2010, Remicade was approved for psoriasis (plaque psoriasis,...read more